[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-365035-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-365035-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ppm1d-mutation-as-a-distinct-feature-of-myeloid-neoplasms-in-b-cell-non-hodgkin-lymphoma-patients-a-retrospective-analysis","PPM1D Mutation as a Distinct Feature of Myeloid Neoplasms in B-Cell Non-Hodgkin Lymphoma Patients - A Retrospective Analysis","","Myeloid neoplasms are the most common secondary blood cancer in B-cell non-Hodgkin lymphoma (BNHL) patients treated with cytotoxic therapies. This retrospective study characterizes genetic and clinicopathologic features of myeloid neoplasms arising after BNHL by comparing MN-BNHL with myeloid neoplasms developing after solid cancer (MN-SC), using clinicopathologic and genetic data from patients diagnosed between 2008 and 2023 and additional NGS when bone marrow genetic data were missing. Sixteen patients developed MN-BNHL; among 11 with NGS, all carried tier 1 mutations, with PPM1D mutations most frequent (73%). PPM1D mutations were significantly more prevalent than in MN-SC, where TP53 mutations predominated, and were linked to prior radioimmunotherapy. MN-BNHL patients with PPM1D mutations showed improved survival, an effect negated by co-occurring TP53 mutations. The findings support a distinct genetic role of PPM1D in BNHL-related myeloid neoplasm development and prognosis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ppm1d-mutation-as-a-distinct-feature-of-myeloid-neoplasms-in-b-cell-non-hodgkin-lymphoma-patients-a-retrospective-analysis/365035/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ppm1d-mutation-as-a-distinct-feature-of-myeloid-neoplasms-in-b-cell-non-hodgkin-lymphoma-patients-a-retrospective-analysis/365035.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-18","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What genetic mutation is identified as a distinct feature in MN-BNHL patients?","Question",{"text":63,"@type":64},"PPM1D mutations are reported as the most frequent genetic alteration in MN-BNHL, occurring in 73% of patients with NGS data.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do PPM1D and TP53 mutations differ between MN-BNHL and MN-SC?",{"text":68,"@type":64},"PPM1D mutations are significantly more prevalent in MN-BNHL than in MN-SC, while TP53 mutations are most common in MN-SC.",{"name":70,"@type":61,"acceptedAnswer":71},"Does PPM1D mutation improve survival, and how does TP53 affect this?",{"text":72,"@type":64},"MN-BNHL patients with PPM1D mutations show improved survival, but the benefit is negated when TP53 mutations are also present.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},365035,1790195167,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Article  \nPPM1D Mutation as a Distinct Feature of Myeloid  \nNeoplasms in B-Cell Non-Hodgkin Lymphoma Patients: A Retrospective Analysis  \nHeyjin Kim 1,2, Jin Kyung Lee 1,*, Young Jun Hong 1, Hye Jin Kang 3, Byung Hyun Byun 4 and Seung-Sook Lee 5  \nAcademic Editors: Tianshun Zhang, Qiushi Wang and Ann Bode  \nReceived: 26 February 2025  \nRevised: 23 March 2025  \nAccepted: 27 March 2025  \nPublished: 31 March 2025  \nCitation: Kim, H.; Lee, J.K.; Hong, Y.J.; Kang, H.J.; Byun, B.H.; Lee, S.-S. PPM1D Mutation as a Distinct Feature of Myeloid Neoplasms in B-Cell Non-Hodgkin Lymphoma Patients: A Retrospective Analysis. Cancers 2025, 17, 1185. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers17071185  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Laboratory Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea; [heyjin@kirams.re.kr](heyjin@kirams.re.kr) (H.K.); [clinchem@kirams.re.kr](clinchem@kirams.re.kr) (Y.J.H.)  \n2 Medical Science Demonstration Center, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea  \n3 Division of Hematology-Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea; [hyejin@kirams.re.kr](hyejin@kirams.re.kr)  \n4 Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea; [nmbbh@kirams.re.kr](nmbbh@kirams.re.kr)  \n5 Department of Pathology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea; [sslee@kirams.re.kr](sslee@kirams.re.kr)  \n* [Correspondence: jklee@kirams.re.kr](Correspondence: jklee@kirams.re.kr)  \nSimple Summary: Myeloid neoplasms are a significant complication for B-cell nonHodgkin lymphoma survivors treated with cytotoxic therapies. This study examined the genetic profiles of myeloid neoplasms following B-cell non-Hodgkin lymphoma, finding PPM1D mutations to be significantly more frequent than in myeloid neoplasms after solid cancers. PPM1D mutations, often with DNMT3A, were associated with improved survival unless TP53 mutations were also present. This suggests the distinct role of PPM1Din myeloid neoplasms development after B-cell non-Hodgkin lymphoma.  \nAbstract: Background/Objectives: Myeloid neoplasms are the most common secondary blood cancer in B-cell non-Hodgkin lymphoma (BNHL) patients treated with cytotoxic therapies. We aimed to characterize the genetic and clinicopathologic features of myeloid neoplasms arising after B-cell non-Hodgkin lymphoma (MN-BNHL) by comparing their features with myeloid neoplasms developing after solid cancer (MN-SC) . Methods: We retrospectively analyzed the clinicopathologic and genetic data of myeloid neoplasm patients diagnosed between 2008 and 2023, categorized as MN-BNHL or MN-SC. Further NGS analysis was performed on available bone marrow samples with missing genetic data. The genetic profiles of myeloid neoplasms between BNHL and solid cancer groups were compared. Results: Sixteen patients developed MN-BNHL. Among the 11 MN-BNHL patients undergoing NGS, all harbored tier 1 mutations. PPM1D mutations (PPM1Dms) were most frequent (73%), followed by DNMT3A (46%) and TP53 (36%) . PPM1Dms were significantly more prevalent than in MN-SC (n = 21), where TP53 mutations were most common (64%) (p \u003C 0.001) . PPM1Dms often co-occurred with DNMT3A. They were associated with prior radioimmunotherapy (relative risk (RR): 3.3 and RR 3.57) . MNBNHL ","cbCaibCDxjER4YDU","https://ap.wps.com/l/cbCaibCDxjER4YDU","pdf",2678288,14,"English","# Introduction\n# Abstract\n# Keywords","[{\"question\":\"What genetic mutation is identified as a distinct feature in MN-BNHL patients?\",\"answer\":\"PPM1D mutations are reported as the most frequent genetic alteration in MN-BNHL, occurring in 73% of patients with NGS data.\"},{\"question\":\"How do PPM1D and TP53 mutations differ between MN-BNHL and MN-SC?\",\"answer\":\"PPM1D mutations are significantly more prevalent in MN-BNHL than in MN-SC, while TP53 mutations are most common in MN-SC.\"},{\"question\":\"Does PPM1D mutation improve survival, and how does TP53 affect this?\",\"answer\":\"MN-BNHL patients with PPM1D mutations show improved survival, but the benefit is negated when TP53 mutations are also present.\"}]","PPM1D Mutation as a Distinct Feature of Myeloid Neoplasms in B-Cell Non-Hodgkin Lymphoma Patients - A Retrospective Analysis | PDF",1790159841,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8128a6ced5cb3cffc60e2d45f3d957ef.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78eb11e731a94323c77281fcaaea763d.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6cbfcfcee29104f615b3d640adb7aa8e.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea04d7e369832d28ab9084bff3769d39.webp",980,1385]